HLB Completes Clinical Trial of Riboceranib Combined with Opdivo

[Asia Economy Reporter Hyunseok Yoo] HL Biopharma announced on the 28th that it has completed a combination clinical trial of Lenvatinib and the immune checkpoint inhibitor Opdivo (Nivolumab) from global pharmaceutical company BMS (Bristol-Myers Squibb) for sarcoma.

The lead oncologist of this clinical trial at the Cancer Center of Southern California, Dr. Sant P Chawla, stated, "The combination trial of Opdivo and Lenvatinib showed significant improvement in patients and was one of the most impressive clinical trials recently conducted." He added, "Some patients were so satisfied that they wished to continue the medication even after the trial ended, and notably, the side effects were manageable."

The combination clinical results with Opdivo are currently undergoing statistical analysis, and the final results will be presented at an international conference. Lenvatinib is also undergoing a global Phase 3 first-line trial for liver cancer in combination with Camrelizumab, an immune checkpoint inhibitor from Chinese pharmaceutical company Hansoh Pharma, which shares the same mechanism as Opdivo. According to the company, these results indirectly confirm the efficacy of combining anti-angiogenic agents with immune checkpoint inhibitors.

Lenvatinib is known to normalize blood vessels around tumors to increase the delivery rate of anticancer drugs and reduce PD-1 expression on immune cells within tumors, thereby enhancing the effect of immune checkpoint inhibitors. A representative from HL Biopharma said, "Currently, Lenvatinib is undergoing various combination clinical trials not only with immune checkpoint inhibitors but also with multiple anticancer drugs," adding, "The value of Lenvatinib in the anticancer drug market is expected to increase."

This content was produced with the assistance of AI translation services.